{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:02:05Z","timestamp":1780923725380,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.resmer.2026.101253","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:16:02Z","timestamp":1770077762000},"page":"101253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progression"],"prefix":"10.1016","volume":"89","author":[{"given":"Paul","family":"Lajoinie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Fallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"du Rusquec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gounant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Giroux-Leprieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1082-0617","authenticated-orcid":false,"given":"Camille","family":"Mehlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10066","key":"10.1016\/j.resmer.2026.101253_bib0001","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.resmer.2026.101253_bib0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non\u2013Small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.resmer.2026.101253_bib0003","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR -mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.resmer.2026.101253_bib0004","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fon-2021-0923","article-title":"MARIPOSA : phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer","volume":"18","author":"Cho","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.resmer.2026.101253_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of Osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resmer.2026.101253_bib0006","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","article-title":"Resistance mechanisms to Osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study","volume":"137","author":"Camille","year":"2019","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.resmer.2026.101253_bib0007","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor\u2013Mutated metastatic non\u2013Small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"10.1016\/j.resmer.2026.101253_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9000","article-title":"Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study","volume":"41","author":"Yang","year":"2023","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.resmer.2026.101253_bib0009","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.annonc.2021.10.007","article-title":"VP9-2021: ORIENT-31: Phase III study of Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy","volume":"33","author":"Lu","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.resmer.2026.101253_bib0010","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of Atezolizumab plus Bevacizumab and chemotherapy in patients with EGFR - or ALK -mutated non\u2013Small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resmer.2026.101253_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","author":"Zhao","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.resmer.2026.101253_bib0012","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without Lazertinib in EGFR-mutant advanced NSCLC after disease progression on Osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.resmer.2026.101253_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.resmer.2026.101253_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107248","article-title":"Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI\u2019s: exploration of efficacy of unselected treatment in a multicenter cohort study","volume":"181","author":"Steendam","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resmer.2026.101253_bib0015","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/cancers16142589","article-title":"Post-progression analysis of EGFR-mutant NSCLC following Osimertinib therapy in real-world settings","volume":"16","author":"Attili","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.resmer.2026.101253_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2024.09.006","article-title":"Treatment patterns and clinical outcomes in patients with EGFR-mutated non\u2013Small-cell lung cancer after progression on Osimertinib","volume":"26","author":"Robinson","year":"2025","journal-title":"Clin Lung Cancer"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:11:59Z","timestamp":1780920719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041226000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":16,"alternative-id":["S2590041226000085"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101253","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progression","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SPLF and Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101253"}}